MapLight Therapeutics
MA - BurlingtonBiotechnology
Focus: MapLight Therapeutics is a Burlington, MA-based biotech company developing optogenetics-based therapies for rare neuropsychiatric diseases. The company is in Series C+ funding stage with active Phase 2 programs targeting autism spectrum disorder, schizophrenia, and Alzheimer's-associated psychosis.
Profile data last refreshed 20h ago · AI intelligence enriched 3w ago
Funding Stage
SERIES C +
Open Jobs
10-1 this month
Stable — net -1 jobs in 30d
2 added, 3 removed. Backfill posture.
Should You Work at MapLight Therapeutics?
AI assessmentStrong fit for early-career researchers and clinical operations professionals seeking deep involvement in novel mechanism discovery; higher risk for those prioritizing financial stability or established commercial infrastructure.
Why Work Here
- Opportunity to work on cutting-edge optogenetics platform technology in high-unmet-need rare neuropsychiatric indications with multiple Phase 2 programs underway.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ML-004
Autism Spectrum DisorderClinical Trials (1)
NCT05889273ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)
Phase 2Help build intelligence for MapLight Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.